Montserrat Rivero
A5101740985- Inflammatory Bowel Disease
- Microscopic Colitis
- Liver Disease Diagnosis and Treatment
- Eosinophilic Esophagitis
- Immunodeficiency and Autoimmune Disorders
- Diagnosis and treatment of tuberculosis
- Autoimmune and Inflammatory Disorders
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Pregnancy and Medication Impact
- Liver Disease and Transplantation
- Biosimilars and Bioanalytical Methods
- Diverticular Disease and Complications
- Liver Diseases and Immunity
- Celiac Disease Research and Management
- Tuberculosis Research and Epidemiology
- Mycobacterium research and diagnosis
- Helicobacter pylori-related gastroenterology studies
- Systemic Lupus Erythematosus Research
- Neuropeptides and Animal Physiology
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Hepatitis Viruses Studies and Epidemiology
- COVID-19 Clinical Research Studies
- Gastric Cancer Management and Outcomes
Marqués de Valdecilla University Hospital
2016-2025
Instituto de Investigación Marqués de Valdecilla
2017-2025
Universidad de Cantabria
2002-2024
Hospital Universitari de Girona Doctor Josep Trueta
2024
Goethe University Frankfurt
2023
University of Miami
2023
Agaplesion Markus Hospital
2023
Hospital Universitario de La Princesa
2019
Hospital Universitario del Sureste
2014-2016
Hospital Universitario Reina Sofía
2016
β-Blockers and endoscopic variceal ligation (EVL) have proven to be valuable methods in the prevention of rebleeding. The aim this study was compare efficacy EVL combined with nadolol versus alone as secondary prophylaxis for bleeding. Patients admitted acute bleeding were treated during emergency endoscopy or sclerotherapy received somatostatin 5 days. At that point, patients randomized receive plus alone. sessions repeated every 10 12 days until varices eradicated. Eighty cirrhosis...
Effectiveness of vedolizumab in real world clinical practice is unknown.To evaluate the short and long-term effectiveness patients with inflammatory bowel disease (IBD).Patients who received at least 1 induction dose were included. was defined based on Harvey-Bradshaw index (HBI) Crohn's (CD) Partial Mayo Score (PMS) ulcerative colitis (UC). Short-term response assessed week 14. Variables associated short-term remission identified by logistic regression analysis. The Kaplan-Meier method used...
The aims of this study were to determine the prevalence fatigue in patients with inflammatory bowel disease [IBD], identify factors associated and its severity, assess impact on quality life [QoL], evaluate relationship between sleep disorders.This was a prospective multicentre conducted at 22 Spanish centres. Consecutive followed IBD Units included. Fatigue evaluated Severity Scale [FSS] Impact [FIS]. Quality assessed using Questionnaire-Short Form [IBDQ-9] Pittsburgh Sleep Index [PSQI],...
The development programm UNIFI has shown promising results of ustekinumab in ulcerative colitis [UC] treatment which should be confirmed clinical practice. We aimed to evaluate the durability, effectiveness, and safety UC real life.Patients included prospectively maintained ENEIDA registry, who received at least one intravenous dose due active [Partial Mayo Score [PMS]>2], were included. Clinical activity effectiveness defined based on PMS. Short-term response was assessed Week 16.A total 95...
(1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe main epidemiological and clinical characteristics at diagnosis evolution disease, explore use drug treatments. (2) Methods: Prospective, population-based nationwide registry. Adult patients diagnosed with IBD-Crohn's (CD), ulcerative colitis (UC) or IBD unclassified (IBD-U)-during 2017 Spain were included followed-up for 1 year. (3) Results: We identified 3611 incident cases during 108 hospitals...
There is conflicting evidence regarding the prevalence of and risk factors for metabolic-associated fatty liver disease (MAFLD) in patients with inflammatory bowel (IBD). We aimed to determine MAFLD IBD patients.Cross-sectional, case-control study included all consecutive treated at 2 different university hospitals. Controls were subjects randomly selected from general population matched by age, sex, type diabetes status, body mass index a 1:2 ratio. was confirmed controlled attenuation...
Background: Golimumab efficacy data in ulcerative colitis (UC) are limited to anti-tumor necrosis factor a (TNF)-naive patients.The aim of this study was assess the short-term and long-term golimumab used as first, second, or third anti-TNF UC real-life clinical setting.Methods: This retrospective multicenter cohort included patients with moderate-to-severe treated golimumab.The primary endpoints were partial Mayo score response, failure-free survival, colectomy-free survival. Results:In 142...
Psoriasis induced by anti-tumor necrosis factor-α (TNF) therapy has been described as a paradoxical side effect.To determine the incidence, clinical characteristics, and management of psoriasis anti-TNF in large nationwide cohort inflammatory bowel disease patients.Patients with were identified from Spanish prospectively maintained Estudio Nacional en Enfermedad Inflamatoria Intestinal sobre Determinantes genéticos y Ambientales registry Grupo Español de Trabajo Croh Colitis Ulcerosa....
Summary Background There are limited data of ustekinumab administered according to the doses recommended in UNITI studies. Aim To assess real‐world, short‐term effectiveness refractory Crohn's disease (CD) Methods Multicentre study CD patients starting after June 2017 at recommend dose (260, 390 or 520 mg based on weight ~6 mg/kg IV week 0 and 90 subcutaneously 8). Values for Harvey‐Bradshaw Index (HBI), C‐reactive protein (CRP) faecal calprotectin (FC) were recorded baseline weeks 8 14....
Summary Background Data on the long‐term administration of ustekinumab in recommended doses are limited. Aim To assess real‐world, effectiveness refractory Crohn's disease (CD). Methods Multi‐centre study CD patients starting at dose, followed for 1 year. Values Harvey‐Bradshaw Index (HBI), endoscopic activity, C‐reactive protein (CRP), and faecal calprotectin (FC) were recorded baseline weeks 26 52. Demographic clinical data, previous treatments, adverse events (AEs) hospitalisations...
Abstract Background and Aims Clinical trials real-life studies with ustekinumab in Crohn’s disease [CD] have revealed a good efficacy safety profile. However, these data are scarcely available elderly patients. Therefore, we aim to assess the effectiveness of patients CD. Methods Elderly [>60 years old] from prospectively maintained ENEIDA registry treated due CD were included. Every patient was matched two controls under 60 age, according anti-tumour necrosis factor use smoking...
Summary Background Thiopurines are the most widely used immunosuppressants in IBD although drug‐related adverse events (AE) occur 20%‐30% of cases. Aim To evaluate safety thiopurines elderly patients Methods Cohort study including all adult ENEIDA registry who received thiopurines. Patients were grouped terms age at beginning thiopurine treatment, specifically those started over 60 years or between 18 and 50 age. Thiopurine‐related AEs registered database compared. Results Out 48 752...
Abstract Background The effectiveness of the switch to another anti–tumor necrosis factor (anti-TNF) agent is not known. aim this study was analyze and safety treatment with a second third anti-TNF drug after intolerance or failure previous in inflammatory bowel disease (IBD) patients. Methods We included patients diagnosed IBD from ENEIDA registry who received prior agent. Results A total 1122 were included. In short term, remission achieved 55% anti-TNF. incidence loss response 19% per...
Abstract Background Factors influencing the exposure to targeted therapies (biologics/JAKi), intestinal resections and hospitalisations in newly diagnosed IBD patients have been scarcely studied. Aim: To identify predictive factors of biologics/JAKi, surgeries, within first five years patients. Methods Prospective, population-based nationwide registry. Adult with [Crohn’s disease (CD), ulcerative colitis (UC) or unclassified (IBD-U)] during 2017 17 Spanish regions were included. Patients who...
Abstract Background Inflammatory bowel disease (IBD) patients may have a higher risk of gastrointestinal bleeding during anticoagulant treatment due to mucosal erosions. Millions worldwide receive classic oral anticoagulants or direct-acting (DOACs).The main indication is stroke prophylaxis in atrial fibrillation (AF), with an increasing prevalence older age groups (8.5% the Spanish population over 60 years old).Anticoagulants (especially DOACs) safety data are limited IBD. Our objective was...
Abstract Background Colectomy is the primary treatment for dysplastic lesions in inflammatory bowel disease (IBD). Since development of advanced endoscopic techniques, management dysplasia evolving. Endoscopic submucosal resection (ESD) could be used selected cases at referral centres as an alternative to colectomy. However, feasibility and safety IBD remains limited. Main aim: To evaluate en-bloc rate need colectomy due ESD failure IBD. Secondary aims: assess complications ESD, local...
Abstract Background Phase III trials have demonstrated the efficacy of risankizumab (RZB), this being first humanized monoclonal IgG1 antibody which targets interleukin 23 p19 subunit, in Crohn’s disease (CD). However, real-world data with drug is limited. The aim our study was to assess effectiveness RZB patients CD. Methods Adult CD that had received treatment ENEIDA registry —a large prospectively maintained Spanish database promoted by Working Group and Colitis (GETECCU)— were included....
Abstract Background and Aims Primary sclerosing cholangitis [PSC] is usually associated with inflammatory bowel disease [IBD]. An increased risk of malignancies, mainly colorectal cancer [CRC] cholangiocarcinoma [CCA], has been reported in PSC-IBD patients. Our aim was to determine the clinical characteristics management PSC IBD patients, factors malignancies. Methods patients were identified from Spanish ENEIDA registry GETECCU. Additional data collected using AEG-REDCap electronic capture...
The pathogenesis of the fulminant hepatitis B is poorly understood and both viral factors hosts immune response play a role. Previous studies in liver tissues patients with chronic showed overexpression Fas antigen this was correlated activity hepatitis. present study done to determine role virological characteristics infection. We studied three B. HBV‐DNA detected by dot‐blot hybridization polymerase chain reaction. S C gene were sequenced. Levels serum soluble enzymoimmunoassays procedure....
Abstract Background Anti–tumor necrosis factor agents (anti-TNFs) are efficacious at preventing the postoperative recurrence (POR) of Crohn disease, as demonstrated in 2 randomized controlled trials. However, real-life data for infliximab or adalimumab this setting scarce. Our aim was to assess both efficiency anti-TNFs early POR disease clinical practice and associated risk factors POR. Methods Patients whom were prescribed prevention within 3 months after ileocolonic resection who had an...